SCHEMBL2795205

SCHEMBL2795205

Cc1ccc2c(C)cc(=O)[nH]c2c1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.67
GLA P06280 3/20 0.67
GAA P10253 3/20 0.67
ALDH1A1 P00352 2/20 0.67
HPGD P15428 2/20 0.67
TP53 P04637 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
RXFP1 Q9HBX9 1/20 0.63
TNKS2 Q9H2K2 8/20 0.62
CYP1A2 P05177 1/20 0.62
CYP2C19 P33261 1/20 0.62
LMNA P02545 2/20 0.53
TNKS O95271 1/20 0.53
KIF11 P52732 1/20 0.52
CA12 O43570 1/20 0.50
CA9 Q16790 1/20 0.50
HSD17B10 Q99714 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5993711 0.86 KDM4E (0.59) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL9724162 0.83 LMNA (0.67) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL31475465 0.83 LMNA (0.67) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL8109985 0.82 KDM4E (0.59) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL29894052 0.81 KDM4E (0.59) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL4736477 0.81 KDM4E (0.59) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL1378769 0.80 TNKS2 (0.75) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL2798886 0.80 KDM4E (0.62) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL8873180 0.80 CA12 (0.56) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL592109 0.80 KDM4E (1.00) KDM4EGLAGAAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108503582-B Microwave-assisted synthesis method of 2- (1H) -quinolinone compounds 湖南科技学院 2020-01-07 CN disclosed
CN-108503582-A The microwave assisted synthesizing method of 2- (1H)-quinolinones compound 湖南科技学院 2018-09-07 CN disclosed
US-20170016907-A1 DUAL-SENSITIZER-CONTAINING LUMINESCENT COMPOUNDS, CONJUGATES, AND USES THEREOF RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2017-01-19 US disclosed
US-9415111-B2 Dual-sensitizer-containing luminescent compounds, conjugates, and uses thereof RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2016-08-16 US disclosed
US-8653069-B2 Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia JIANGSU HENGYI PHARMACEUTICAL CO., LTD. (CN) 2014-02-18 US disclosed
US-8524738-B2 Quinolinones and quinoxalinones as antibacterial composition TOYAMA CHEMICAL CO., LTD. (JP) 2013-09-03 US disclosed
US-8524738-B2 Quinolinones and quinoxalinones as antibacterial composition TOYAMA CHEMICAL CO., LTD. (JP) 2013-09-03 US disclosed
US-8329694-B2 Quinoxalinones as antibacterial composition TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8329694-B2 Quinoxalinones as antibacterial composition TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8329694-B2 Quinoxalinones as antibacterial composition TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-20100168418-A1 NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2010-07-01 US disclosed
US-20100168418-A1 NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2010-07-01 US disclosed
US-7655688-B2 Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-02 US disclosed
US-7655688-B2 Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-02 US disclosed
US-7632651-B2 Molecular modification assays MDS ANALYTICAL TECHNOLOGIES (US) INC. (US) 2009-12-15 US disclosed
US-7632651-B2 Molecular modification assays MDS ANALYTICAL TECHNOLOGIES (US) INC. (US) 2009-12-15 US disclosed
EP-1900732-A1 NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2008-03-19 EP disclosed
WO-2008024634-A1 PYRIMDINE COMPOUNDS USEFUL AS KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-02-28 WO disclosed
US-4187310-A ANTIINFLAMMATORY AGENT, ANALGESICS, ENZYME INHIBITORS IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1980-02-05 US disclosed
US-4138490-A Analgesic compositions containing 1,2-dihydro-2-oxoquinol-4-ylpropionic acid derivatives IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1979-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168418-A1 NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF ROS1, NOX1, ARG1 KDM4E 2360/4885GLA 3562/4885GAA 4764/4885
US-20170016907-A1 DUAL-SENSITIZER-CONTAINING LUMINESCENT COMPOUNDS, CONJUGATES, AND USES THEREOF DYRK4, DYRK2, DYRK3 KDM4E 2347/4885GLA 1328/4885GAA 473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.